Travere Therapeutics, Inc. (TVTX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 198 | 132 | 109 | 145 | 233 | 491 | 591 | 725 |
| Operating profit | $m | -63 | -40 | ||||||
| Net profit | $m | -169 | -180 | -278 | -111 | -322 | -26 | -43 | -1 |
| EPS reported | $ | -0.56 | -0.49 | ||||||
| Operating cashflow per share | $ | 0.42 | 0.99 | ||||||
| Capex per share | $ | 0.65 | 0.20 | ||||||
| FCF per share | $ | -0.23 | 0.79 | ||||||
| Free cash flow | $m | -20 | 52 | ||||||
| Net debt | $m | -11 | 114 | ||||||
| Book value equity | $m | 115 | 25 | ||||||
| Book value per share | $ | 1.29 | 0.26 | ||||||
| Number of shares | m | 89.21 | 93.48 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 29.69 | 139.01 | ||||||
| P/S LTM | x | 6.95 | 5.76 | ||||||
| P/FCF LTM | x | -167.32 | 66.17 | ||||||
| EV/EBITDA LTM | x | 164.03 | 2,360.42 | ||||||
| EV/Sales LTM | x | 7.43 | 10.46 | ||||||
| Earnings Yield LTM | % | -0.75% | -0.76% | ||||||
| FCF Yield | % | -0.60% | +1.51% | ||||||
| Quality | |||||||||
| ROE | % | -22.25% | -55.79% | ||||||
| ROIC | % | -13.95% | -6.19% | ||||||
| Operating margin | % | -12.80% | -6.84% | ||||||
| Gross margin | % | +97.89% | +94.41% | ||||||
| FCF/Sales | % | -4.15% | +12.46% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +110.45% | +153.60% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.06 | 0.08 | ||||||
| Net Debt/EBITDA | x | 10.61 | 323.30 | ||||||
| EBIT/Net interest | x | -5.85 | -4.27 | ||||||
| Net debt/market cap | % | +9.14% | +10.70% | ||||||
| Net debt/Equity | x | -0.10 | 4.63 | ||||||
| Gross debt/equity | x | 2.86 | 25.16 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Travere Therapeutics, Inc. (TVTX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free